147 related articles for article (PubMed ID: 38642249)
1. Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer.
Huang Z; Zhou L; Zheng H; Zhan M
Int J Clin Pharm; 2024 Apr; ():. PubMed ID: 38642249
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
Zhang PF; Xie D; Li Q
Tumori; 2020 Oct; 106(5):400-405. PubMed ID: 32354261
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
Peng Z; Hou X; Huang Y; Xie T; Hua X
BMC Cancer; 2020 Oct; 20(1):990. PubMed ID: 33050905
[TBL] [Abstract][Full Text] [Related]
5. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Dasari A; Sobrero A; Yao J; Yoshino T; Schelman W; Yang Z; Chien C; Kania M; Tabernero J; Eng C
Future Oncol; 2021 Aug; 17(24):3151-3162. PubMed ID: 33993740
[TBL] [Abstract][Full Text] [Related]
6. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A; Lonardi S; Garcia-Carbonero R; Elez E; Yoshino T; Sobrero A; Yao J; García-Alfonso P; Kocsis J; Cubillo Gracian A; Sartore-Bianchi A; Satoh T; Randrian V; Tomasek J; Chong G; Paulson AS; Masuishi T; Jones J; Csőszi T; Cremolini C; Ghiringhelli F; Shergill A; Hochster HS; Krauss J; Bassam A; Ducreux M; Elme A; Faugeras L; Kasper S; Van Cutsem E; Arnold D; Nanda S; Yang Z; Schelman WR; Kania M; Tabernero J; Eng C;
Lancet; 2023 Jul; 402(10395):41-53. PubMed ID: 37331369
[TBL] [Abstract][Full Text] [Related]
7. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
[TBL] [Abstract][Full Text] [Related]
8. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
Li J; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Xu R; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Shen L; Chen H; Wang S; Wang H; Fan S; Guo X; Wang N; Han R; Zhang B; Qin S
Adv Ther; 2020 Nov; 37(11):4585-4598. PubMed ID: 32901330
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
[TBL] [Abstract][Full Text] [Related]
10. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
Wan Y; Luo D
J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
[TBL] [Abstract][Full Text] [Related]
11. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38186268
[TBL] [Abstract][Full Text] [Related]
13. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
[TBL] [Abstract][Full Text] [Related]
14. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
Zhang Y; Zou JY; Wang Z; Wang Y
Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
[TBL] [Abstract][Full Text] [Related]
15. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Shi Y; Wan X; Tan C; Li J; Peng L
Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
[TBL] [Abstract][Full Text] [Related]
16. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
[TBL] [Abstract][Full Text] [Related]
17. Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.
Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Zhang Q; Su W; Guo X; Li J
Onco Targets Ther; 2021; 14():4439-4450. PubMed ID: 34408440
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
Zhu C; Han G; Wu B
BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
[TBL] [Abstract][Full Text] [Related]
19. The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer.
Song Y; Qu T; Zhang H; Sun Y; Cui C; Chi Y; Zhang W; Wang X; Yang L
Cancer Manag Res; 2021; 13():6199-6205. PubMed ID: 34393513
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Fusco MJ; Casak SJ; Mushti SL; Cheng J; Christmas BJ; Thompson MD; Fu W; Wang H; Yoon M; Yang Y; Moore JN; Bi Y; Nan Y; Long CE; Auth D; Rahman NA; Tang S; Pazdur R; Fashoyin-Aje LA; Kluetz PG; Lemery SJ
Clin Cancer Res; 2024 May; ():. PubMed ID: 38809262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
